444 related articles for article (PubMed ID: 16491367)
1. Clinical study comparing the effects of sequential hormone replacement therapy with oestradiol/dydrogesterone and conjugated equine oestrogen/norgestrel on lipids and symptoms.
Cieraad D; Conradt C; Jesinger D; Bakowski M
Arch Gynecol Obstet; 2006 May; 274(2):74-80. PubMed ID: 16491367
[TBL] [Abstract][Full Text] [Related]
2. Effect of conjugated equine estrogen in combination with two different progestogens on the risk factors of coronary heart disease in postmenopausal Chinese women in Taiwan: a randomized one-year study.
Chang TC; Lien YR; Chen M; Cheng SP; Chen RJ; Chow SN
Acta Obstet Gynecol Scand; 2004 Jul; 83(7):661-6. PubMed ID: 15225192
[TBL] [Abstract][Full Text] [Related]
3. Efficacy comparison of Pueraria mirifica (PM) against conjugated equine estrogen (CEE) with/without medroxyprogesterone acetate (MPA) in the treatment of climacteric symptoms in perimenopausal women: phase III study.
Chandeying V; Sangthawan M
J Med Assoc Thai; 2007 Sep; 90(9):1720-6. PubMed ID: 17957910
[TBL] [Abstract][Full Text] [Related]
4. A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects on symptom control, bleeding pattern, lipid profile and tolerability.
Baracat EC; Barbosa IC; Giordano MG; Haidar MA; Marinho RM; Menegocci JC; Morais KM; Tomaz G; Wehba S
Climacteric; 2002 Mar; 5(1):60-9. PubMed ID: 11974560
[TBL] [Abstract][Full Text] [Related]
5. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids.
Rozenberg S; Ylikorkala O; Arrenbrecht S
Int J Fertil Womens Med; 1997; 42 Suppl 2():376-87. PubMed ID: 9397385
[TBL] [Abstract][Full Text] [Related]
6. Oral ultra-low dose continuous combined hormone replacement therapy with 0.5 mg 17β-oestradiol and 2.5 mg dydrogesterone for the treatment of vasomotor symptoms: results from a double-blind, controlled study.
Stevenson JC; Durand G; Kahler E; Pertyński T
Maturitas; 2010 Nov; 67(3):227-32. PubMed ID: 20688442
[TBL] [Abstract][Full Text] [Related]
7. Effect of hormone replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women. Influence of various progestogens and duration of therapy.
Kim CJ; Min YK; Ryu WS; Kwak JW; Ryoo UH
Arch Intern Med; 1996 Aug 12-26; 156(15):1693-700. PubMed ID: 8694668
[TBL] [Abstract][Full Text] [Related]
8. 1 and 2 mg 17beta-estradiol combined with sequential dydrogesterone have similar effects on the serum lipid profile of postmenopausal women.
Stevenson JC; Rioux JE; Komer L; Gelfand M
Climacteric; 2005 Dec; 8(4):352-9. PubMed ID: 16390770
[TBL] [Abstract][Full Text] [Related]
9. [Effect of combined conjugated estrogen-medrogestone replacement therapy on lipid profiles, climacteric symptoms and the endometrium].
Belaisch J; Nappi C; Affinito P; De Gezelle H; Botelho M; Oliveira HM; Martinez-Oliveira J; Gonzaga F
J Gynecol Obstet Biol Reprod (Paris); 2000 Feb; 29(1):29-40. PubMed ID: 10675831
[TBL] [Abstract][Full Text] [Related]
10. A 1-year comparison of the efficacy and clinical tolerance in postmenopausal women of two hormone replacement therapies containing estradiol in combination with either norgestrel or trimegestone.
Meuwissen JH; Beijers-De Bie L; Vihtamaki T; Tuimala R; Siseles N; Magaril C; The HS; Houben PW; Murga M; Spielmann D; De Villiers TJ
Gynecol Endocrinol; 2001 Oct; 15(5):349-58. PubMed ID: 11727357
[TBL] [Abstract][Full Text] [Related]
11. The effect of a novel vaginal ring delivering oestradiol acetate on climacteric symptoms in postmenopausal women.
Buckler H; Al-Azzawi F;
BJOG; 2003 Aug; 110(8):753-9. PubMed ID: 12892687
[TBL] [Abstract][Full Text] [Related]
12. [Hormone replacement therapy with 17 beta-estradiol dydrogesterone: results of a 3-month open-label study].
Grisar J; Travica S; Metka M; Pietschmann P
Wien Klin Wochenschr; 1999 Dec; 111(24):1035-43. PubMed ID: 10677891
[TBL] [Abstract][Full Text] [Related]
13. Comparative effects of conventional hormone replacement therapy and tibolone on climacteric symptoms and sexual dysfunction in postmenopausal women.
Ziaei S; Moghasemi M; Faghihzadeh S
Climacteric; 2010 Apr; 13(2):147-56. PubMed ID: 19731119
[TBL] [Abstract][Full Text] [Related]
14. A two-year, double-blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women. Effects on bone mineral density, symptoms and lipid profiles.
Barrett-Connor E; Young R; Notelovitz M; Sullivan J; Wiita B; Yang HM; Nolan J
J Reprod Med; 1999 Dec; 44(12):1012-20. PubMed ID: 10649811
[TBL] [Abstract][Full Text] [Related]
15. The effects of 17 beta-oestradiol plus dydrogesterone compared with conjugated equine oestrogens plus medroxyprogesterone acetate on lipids, apolipoproteins and lipoprotein(a).
de Kraker AT; Kenemans P; Smolders RG; Kroeks MV; van der Mooren MJ
Maturitas; 2004 Nov; 49(3):253-63. PubMed ID: 15488354
[TBL] [Abstract][Full Text] [Related]
16. Comparative controlled trial of a novel oral estrogen therapy, estradiol acetate, for relief of menopause symptoms.
Utian WH; Speroff L; Ellman H; Dart C
Menopause; 2005; 12(6):708-15. PubMed ID: 16278614
[TBL] [Abstract][Full Text] [Related]
17. Effects of low and high dose oestradiol and dydrogesterone therapy on insulin and lipoprotein metabolism in healthy postmenopausal women.
Godsland IF; Manassiev NA; Felton CV; Proudler AJ; Crook D; Whitehead MI; Stevenson JC
Clin Endocrinol (Oxf); 2004 May; 60(5):541-9. PubMed ID: 15104556
[TBL] [Abstract][Full Text] [Related]
18. Medroxyprogesterone and conjugated oestrogen are equivalent for hot flushes: a 1-year randomized double-blind trial following premenopausal ovariectomy.
Prior JC; Nielsen JD; Hitchcock CL; Williams LA; Vigna YM; Dean CB
Clin Sci (Lond); 2007 May; 112(10):517-25. PubMed ID: 17419685
[TBL] [Abstract][Full Text] [Related]
19. The effect of hormone replacement therapy on the levels of serum lipids, apolipoprotein AI, apolipoprotein B and lipoprotein (a) in Turkish postmenopausal women.
Bayrak A; Aldemir DA; Bayrak T; Corakçi A; Dursun P
Arch Gynecol Obstet; 2006 Aug; 274(5):289-96. PubMed ID: 16810536
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular risk markers during treatment with estradiol and trimegestone or dydrogesterone.
Hellgren M; Conard J; Norris L; Kluft C
Maturitas; 2009 Mar; 62(3):287-93. PubMed ID: 19268506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
